COOH-terminal clustering of autoantibody and T-cell determinants on the structure of GAD65 provide insights into the molecular basis of autoreactivity.
OBJECTIVE
To gain structural insights into the autoantigenic properties of GAD65 in type 1 diabetes, we analyzed experimental epitope mapping data in the context of the recently determined crystal structures of GAD65 and GAD67, to allow "molecular positioning" of epitope sites for B- and T-cell reactivity.


METHODS
Data were assembled from analysis of reported effects of mutagenesis of GAD65 on its reactivity with a panel of 11 human monoclonal antibodies (mAbs), supplemented by use of recombinant Fab to cross-inhibit reactivity with GAD65 by radioimmunoprecipitation of the same mAbs.


RESULTS
The COOH-terminal region on GAD65 was the major autoantigenic site. B-cell epitopes were distributed within two separate clusters around different faces of the COOH-terminal domain. Inclusion of epitope sites in the pyridoxal phosphate-and NH(2)-terminal domains was attributed to the juxtaposition of all three domains in the crystal structure. Epitope preferences of different mAbs to GAD65 aligned with different clinical expressions of type 1 diabetes. Epitopes for four of five known reactive T-cell sequences restricted by HLA DRB1*0401 were aligned to solvent-exposed regions of the GAD65 structure and colocalized within the two B-cell epitope clusters. The continuous COOH-terminal epitope region of GAD65 was structurally highly flexible and therefore differed markedly from the equivalent region of GAD67.


CONCLUSIONS
Structural features could explain the differing antigenicity, and perhaps immunogenicity, of GAD65 versus GAD67. The proximity of B- and T-cell epitopes within the GAD65 structure suggests that antigen-antibody complexes may influence antigen processing by accessory cells and thereby T-cell reactivity.
Fenalti
Gustavo
G
Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria 3800, Australia.
Hampe
Christiane S
CS
Arafat
Yasir
Y
Law
Ruby H P
RH
Banga
J Paul
JP
Mackay
Ian R
IR
Whisstock
James C
JC
Buckle
Ashley M
AM
Rowley
Merrill J
MJ
D000911:Antibodies, Monoclonal; D001323:Autoantibodies; D001327:Autoimmune Diseases / Q000201:enzymology / Q000276:immunology; D001402:B-Lymphocytes / Q000276:immunology*; D001666:Binding Sites, Antibody; D018360:Crystallography, X-Ray; D003922:Diabetes Mellitus, Type 1 / Q000201:enzymology / Q000276:immunology; D019281:Dimerization; D000939:Epitopes / Q000032:analysis; D005968:Glutamate Decarboxylase / Q000737:chemistry* / Q000235:genetics / Q000276:immunology*; D006801:Humans; D007700:Kinetics; D008958:Models, Molecular; D016296:Mutagenesis; D010446:Peptide Fragments / Q000737:chemistry / Q000276:immunology; D011487:Protein Conformation; D013601:T-Lymphocytes / Q000276:immunology*
D000911:Antibodies, Monoclonal; D001323:Autoantibodies; D000939:Epitopes; D010446:Peptide Fragments; D005968:Glutamate Decarboxylase; C402565:glutamate decarboxylase 1; C401141:glutamate decarboxylase 2